



Your Submission to Coronary Artery Disease

1 pesan

Coronary Artery Disease <em@editorialmanager.com>
Balas ke: Coronary Artery Disease <kclyde@crf.org>
Kepada: I Gde Rurus Suryawan <igde.rurus.s@fk.unair.ac.id>

Min, 23 Mei 2021 pukul 06.29

May 22, 2021

RE: CAD-D-21-00221, entitled "An Outlook of Coronary Stent Infection: A Systematic Review"

Dear Dr. Suryawan,

The comments from the reviewers are enclosed below. The reviewers and editors believe that your studies are of potential interest to our readers but feel that substantial revision would be necessary before the paper could be considered again for publication in Coronary Artery Disease. At this time, no commitment regarding acceptance can be made. Note: even if you are able to make substantial revisions, we are able to accept less than 50% of manuscripts which are resubmitted as de novo submissions.

If you are willing to significantly revise the manuscript taking into consideration the suggestions of the reviewers, we will send the revised paper to either the original reviewers or to a second set of reviewers for their appraisal. Please include with your revised submission an itemized, point-by-point response to the comments of the reviewers. The revisions should be completed by Jun 21, 2021 to avoid being considered as a new submission.

For manuscripts where English grammar revisions are suggested and required per Reviewers and Editors, the Journal recommends the assistance of professional services. A selection of services may be found at the link: <https://wkauthorservices.editage.com/>

To submit a revision, go to <https://www.editorialmanager.com/cad/> and log in as an Author. You will see a menu item called "Submission Needing Revision." Please click on this item to obtain your submission record and begin the revision process.

Your username is: I Gde Rurus Suryawan
[click here to reset your password](#)

OPEN ACCESS

If you would like your submission, if accepted, to be open access, please complete the following steps. Further information is available at <http://links.lww.com/LWW-ES/A48>.

1. A License to Publish (LTP) form must be completed for your submission to be made open access. Please download the form from <http://links.lww.com/LWW-ES/A49>, sign it, and submit the file as part of your revision (using the Attach Files submission step in Editorial Manager).
2. Upon acceptance of your submission, you will receive an Open Access Publication Charge letter from the Journal's Publisher, Wolters Kluwer, and within instructions on how to submit any open access charges. The email will be from publicationservices@copyright.com with the subject line 'Please Submit Your Open Access Article Publication Charge(s)'. The cost for publishing an article as open access can be found at <https://wkauthorservices.editage.com/open-access/hybrid.html>

With Kind Regards,

Dr. William Penny

Associate Editor

Dr. Ori Ben-Yehuda
Editor-in-Chief
Coronary Artery Disease

Reviewer Comments:

The authors present a summarized systematic review (following PRISMA guidelines) of the clinical presentation, causative pathogens, diagnosis, and treatment of reported Coronary Stent Infection (CSI)--34 CSI cases from 32 case reports.

Most cases were reported from India and described male patients (88.24%), age range 38 to 86 years old, with symptom onset mostly in the first week after stent implantation and mortality rate 26.47%. Staphylococcus aureus and Pseudomonas aeruginosa were the most common pathogens.

Some issues to address:

1. Pg. 1: RE: "Coronary Artery Disease (CAD) is one of the major health problem world. Estimation of 15.5 million adults reported to have CAD." Please review and cite reference (some references state that ischemic heart disease affects over 125 million people world wide).
2. How many of the reports of CSI were met the criteria described on Pg. 8 of "definitive diagnosis of CSI... based on surgical specimen or post-mortem examination revealing infected coronary artery stent complex"? This should be included in Table 1. The use of the criteria for "possible" CSI diagnosis proposed by Dieter (over 20 years ago) using 3 or more conditions such as fever without a clear focus, leukocytosis, bacteremia, ACS and recent stenting is very broad.
Are many of the cases in this summary actually suspected or possible (rather than definitive) CSI?
3. RE: "Cultures and coronary angiography were the most common diagnostic method in CSI." How did coronary angiography contribute to the diagnosis—finding of an aneurysm or pseudoaneurysm? Coronary angiographic findings are not included in the above diagnostic criteria. Does "Aneurysms were the most frequent abnormalities in infected stent." refer to those stents with definitive evidence of infection? Note that many of the "first hit" events described on pg. 8 (atherosclerosis, trauma, coronary manipulation, or any vascular inflammation) that cause "degeneration and (a) weakened artery wall" may lead to aneurysm or pseudoaneurysm without infection.
4. Also, Pg. 7 states "In addition, coronary angiography was the most favourable diagnostic modalities." Favourable in what way?
5. In Table 1, TC denotes tissue culture. Did this tissue involve the infected stent? How was this obtained from the patients who survived? Were the infected stents and/or coronary segments removed at surgery? Does "abscess" in the second to last column in Table 1 refer to an abscess at the coronary stent site?
6. RE: "More than 90% of the cases mentioned various antibiotics, and more than 75% mentioned surgery." What was the range of duration antibiotic Rx? What surgeries were performed?
7. RE: "Conditions such as sterility inadequacy..." How often was re-utilization of balloons, wires and other supplies designed for single patient use cited as associated with the suspected or definitive CSI?
8. Table 1: Regarding the column titled "Coronary Pathology": Does this mean the coronary "abnormality," or is it meant to indicate findings from a pathologic (tissue) examination?
9. The paper needs extensive proof reading as it pertains to grammar and syntax

Complete Revision Instructions:

PRELIMINARY STEPS:

1. Click on the "Submissions Needing Revision" link.
2. To view the previous decision letter and reviewer comments, please click the blue decision term listed under the View Decision menu. If you would like to download the previous manuscript in order to make revisions, click on "Download Files" under the Action menu.

RESUBMISSION STEPS:

3. To BEGIN the RESUBMISSION: Click "Submit Revision" under the Action menu.
4. Proof each screen to ensure the information is still correct (the Title, Authors, etc), then click Next at the bottom of each page.
5. On the Attach Files screen, be sure to click beside each previous submission item that you would like included in the following submission.

6. Now, as you did previously, simply upload the parts of your manuscript. When you are finished, please click Next.
7. Click "Build PDF for My Approval."
8. Click "Go to Submissions Waiting for Authors Approval."
9. Wait for the PDF to Build. When it has been built, you will see the link "View Submission" in the Action menu. Click "View Submission," and open the manuscript in order to proof your work.
10. If you find problems with the manuscript, please click "Edit Submission" from the Action menu. Make the appropriate changes, beginning again at step 3.
11. If you find no problems with the manuscript, please click "Approve Submission" from the Action menu. Your re-submission is now complete!

In compliance with data protection regulations, you may request that we remove your personal registration details at any time. ([Remove my information/details](#)). Please contact the publication office if you have any questions.



CAD-D-21-00221 Query

4 pesan

Lutchmeenaraidoo, Hema <H.Lutchmeenaraidoo@wolterskluwer.com>
Kepada: igde.rurus.s@fk.unair.ac.id <igde.rurus.s@fk.unair.ac.id>
Cc: kevin.luke-2016@fk.unair.ac.id <kevin.luke-2016@fk.unair.ac.id>

Rab, 18 Agu 2021 pukul 16.17

Dear Dr I Gde Rurus Suryawan,

Hope you are well.

While working in your manuscript, we noticed that the citation for Table 1 is missing in the proof text. May I kindly request you to inform us where to cite Table 1 in the text please.

Many Thanks

Kind Regards,

Hema Lutchmeenaraidoo

Production Editor

Health Learning, Research & Practice

Wolters Kluwer

Citi Building

41st Floor

25 Canada Square

Canary Wharf

London E14 5LQ

UK

+ 44 (0) 203 197 6697 tel.

H.Lutchmeenaraidoo@wolterskluwer.com

<http://www.wolterskluwer.com/>

Confidentiality Notice: This email and its attachments (if any) contain confidential information of the sender. The information is intended only for the use by the direct addressees of the original sender of this email. If you are not an intended recipient of the original sender (or responsible for delivering the message to such person), you are hereby notified that any review, disclosure, copying, distribution or the taking of any action in reliance of the contents of and attachments to this email is strictly prohibited. If you have received this email in error, please immediately notify the sender at the address shown herein and permanently delete any copies of this email (digital or paper) in your possession.

gde rurus suryawan I <igde.rurus.s@fk.unair.ac.id>

Rab, 18 Agu 2021 pukul 20.27

Kepada: Lutchmeenaraidoo, Hema <H.Lutchmeenaraidoo@wolterskluwer.com>

Dear Hema Lutchmeenaraidoo,

Thank you for the information. Table 1 should be cited in the results section, "selected studies and baseline characteristics" in the last line of the paragraph. We had annotated the PDF.

In the last article preview, we noticed a citation mistake in the table. We had a revision note in the query form. Has the mistake been revised?

Thankyou

[Kutipan teks disembunyikan]

Lutchmeenaraidoo, Hema <H.Lutchmeenaraidoo@wolterskluwer.com>

Kam, 19 Agu 2021 pukul 16.50

Kepada: gde rurus suryawan I <igde.rurus.s@fk.unair.ac.id>

Dear Dr I Gde Rurus Suryawan,

Thank you for the Table 1 citation.

The revised proof is not ready yet. once it is ready, we will send it to you for a final review and you can check the corrections made to the Table.

Thanks

Hema Lutchmeenaraidoo

Production Editor

Health Learning, Research & Practice

+ 44 (0) 203 197 6697 tel.

H.Lutchmeenaraidoo@wolterskluwer.com

<http://www.wolterskluwer.com/>

From: gde rurus suryawan I <igde.rurus.s@fk.unair.ac.id>
Sent: 18 August 2021 14:28
To: Lutchmeenaraidoo, Hema <H.Lutchmeenaraidoo@wolterskluwer.com>
Subject: Re: CAD-D-21-00221 Query

Caution, this email may be from a sender outside Wolters Kluwer. Verify the sender and know the content is safe.

[Kutipan teks disembunyikan]

gde rurus suryawan I <igde.rurus.s@fk.unair.ac.id>
Kepada: Lutchmeenaraidoo, Hema <H.Lutchmeenaraidoo@wolterskluwer.com>

Kam, 9 Sep 2021 pukul 19.06

Dear Editor,

We are pleased that our manuscript had been recently published in Coronary Artery Disease Journal. However, we had not received any final proofread for the manuscript since we had minor revision regarding the citation. Looking forward for the reply. Thank you very much

[Kutipan teks disembunyikan]



CAD Decision

1 pesan

Coronary Artery Disease <em@editorialmanager.com>
Balas ke: Coronary Artery Disease <kclyde@crf.org>
Kepada: I Gde Rurus Suryawan <igde.rurus.s@fk.unair.ac.id>

Sen, 9 Agu 2021 pukul 06.21

CC: wpenny@ucsd.edu

Aug 08, 2021

RE: CAD-D-21-00221R3, entitled "Coronary Stent Infection: A Systematic Review"

Dear Dr. Suryawan,

It is a pleasure to inform you that your work has been accepted for publication in Coronary Artery Disease. All manuscript materials will be forwarded immediately to the production staff for placement in an upcoming issue.

We would like to offer you FREE access to the electronic table of contents (eTOC) to keep you updated on content of each issue of the journal Coronary Artery Disease, including the issue that will feature your publication. If you wish to sign up for eTOC alerts for Coronary Artery Disease, please do so at <http://journals.lww.com/coronary-artery/pages/etoc.aspx>

OPEN ACCESS

**** Coronary Artery Disease has recently transitioned to a new Open Access payment platform. If your manuscript was submitted prior to March 9, 2021, please contact the Coronary Artery Disease Editorial Office. If your manuscript was submitted after March 9, 2021, please disregard this message. ****

If you indicated in the revision stage that you would like your submission, if accepted, to be made open access, please go directly to step 2. If you have not yet indicated that you would like your accepted article to be open access, please follow the steps below to complete the process:

1. Notify the journal office via email that you would like this article to be available open access. Please send your Email to kclyde@crf.org. Please include your article title and manuscript number.
2. A License to Publish (LTP) form must be completed for your submission to be made available open access. Please download the form from <http://links.lww.com/LWW-ES/A49>, sign it, and Email the completed form to the journal office.
3. You will be receiving an Open Access Publication Charge letter from the Journal's Publisher, Wolters Kluwer, and within instructions on how to submit any open access charges. The email will be from publicationservices@copyright.com with the subject line 'Please Submit Your Open Access Article Publication Charge(s)'. **Please complete payment of the Open Access charges within 48 hours of receipt.**

Thank you for submitting your interesting work to the journal.

With Kind Regards,

Dr. William Penny

Associate Editor

Dr. Ori Ben-Yehuda
Editor-in-Chief
Coronary Artery Disease

<https://www.editorialmanager.com/cad/>

Your username is: I Gde Rurus Suryawan
[click here to reset your password](#)

In compliance with data protection regulations, you may request that we remove your personal registration details at any time. ([Remove my information/details](#)). Please contact the publication office if you have any questions.



CAD-D-21-00221 Final proof

7 pesan

Lutchmeenaraidoo, Hema <H.Lutchmeenaraidoo@wolterskluwer.com>

Sen, 4 Okt 2021 pukul 16.21

Kepada: gde rurus suryawan I <igde.rurus.s@fk.unair.ac.id>

Cc: kevin.luke-2016@fk.unair.ac.id <kevin.luke-2016@fk.unair.ac.id>, rafiv.fasya.agustianto-2016@fk.unair.ac.id <rafiv.fasya.agustianto-2016@fk.unair.ac.id>, eka.prasetya.budi-2017@fk.unair.ac.id <eka.prasetya.budi-2017@fk.unair.ac.id>

Dear Dr I Gde Rurus Suryawan,

Hope you are well.

Please find attached a copy of the final proof of **CAD-D-21-00221** for your review. Could you please check through the proof and let me know if all is fine before its publication.

I would be grateful if you could please get back to me with your feedback within 2 days please.

Many Thanks

Kind Regards

Hema Lutchmeenaraidoo

Production Editor

Health Learning, Research & Practice

Wolters Kluwer

Citi Building

41st Floor

25 Canada Square

Canary Wharf

London E14 5LQ

UK

+ 44 (0) 203 197 6697 tel.

H.Lutchmeenaraidoo@wolterskluwer.com

Confidentiality Notice: This email and its attachments (if any) contain confidential information of the sender. The information is intended only for the use by the direct addressees of the original sender of this email. If you are not an intended recipient of the original sender (or responsible for delivering the message to such person), you are hereby notified that any review, disclosure, copying, distribution or the taking of any action in reliance of the contents of and attachments to this email is strictly prohibited. If you have received this email in error, please immediately notify the sender at the address shown herein and permanently delete any copies of this email (digital or paper) in your possession.

gde rurus suryawan I <igde.rurus.s@fk.unair.ac.id>

Sen, 4 Okt 2021 pukul 18.14

Kepada: Lutchmeenaraidoo, Hema <H.Lutchmeenaraidoo@wolterskluwer.com>

Dear Production Editor,

Thank you very much for the revision regarding our manuscript, we had proofread the manuscript. However, there was 2 minor revision.

1. The reference in last sentence of discussion "Meanwhile, previous reviews included all CSI cases, which is the most likely reason for the higher mortality rates" should be cited as reference no 41 (Restrepo et al.) instead of 42 (Kumbar et al)
2. While sentence in study limitation section line 6 "However, hemodialysis and surgery are considered significant infection sources, which may cause bias." should be cited as reference no 42 (Kumbar et al.) instead of 41 (Restrepo et al)

Thank you for the information. we are very honored and pleased that our manuscript is qualified in the Coronary Artery Disease journal.

Best regards,

I Gde Rurus Suryawan

[Kutipan teks disembunyikan]

gde rurus suryawan I <igde.rurus.s@fk.unair.ac.id>

Kam, 25 Nov 2021 pukul 07.09

Kepada: Lutchmeenaraidoo, Hema <H.Lutchmeenaraidoo@wolterskluwer.com>

Dear Production Editor,

Recently, we have noted 2 minor revision of our manuscript final proof. How is the update of our final proof of the manuscript?

[Kutipan teks disembunyikan]

Lutchmeenaraidoo, Hema <H.Lutchmeenaraidoo@wolterskluwer.com>

Kam, 9 Des 2021 pukul 23.22

Kepada: gde rurus suryawan I <igde.rurus.s@fk.unair.ac.id>

Dear Dr I Gde Rurus Suryawan,

Thank you for your email.

The corrections were incorporated successfully. Please find attached the final revised proof after the corrections were incorporated.

Many Thanks

Kind Regards,

Hema Lutchmeenaraidoo

Production Editor

Health Learning, Research & Practice

+ 44 (0) 203 197 6697 tel.

H.Lutchmeenaraidoo@wolterskluwer.com

<http://www.wolterskluwer.com/>

From: gde rurus suryawan I <igde.rurus.s@fk.unair.ac.id>
Sent: 25 November 2021 00:10
To: Lutchmeenaraidoo, Hema <H.Lutchmeenaraidoo@wolterskluwer.com>
Subject: Re: CAD-D-21-00221 Final proof

Caution, this email may be from a sender outside Wolters Kluwer. Verify the sender and know the content is safe.

[Kutipan teks disembunyikan]

gde rurus suryawan I <igde.rurus.s@fk.unair.ac.id> Jum, 10 Des 2021 pukul 06.06
Kepada: Lutchmeenaraidoo, Hema <H.Lutchmeenaraidoo@wolterskluwer.com>

Dear Production Editor,

Thank you for sending us the final proof. We have read it, and no further correction is needed.
Will we get a clean version of published manuscript pdf next?

Best regards,
I Gde Rurus Suryawan
[Kutipan teks disembunyikan]

gde rurus suryawan I <igde.rurus.s@fk.unair.ac.id> Sen, 3 Jan 2022 pukul 13.00
Kepada: Lutchmeenaraidoo, Hema <H.Lutchmeenaraidoo@wolterskluwer.com>

Dear Production Editor,

Can we get the published version of our manuscript?

Best regards,

I Gde Rurus Suryawan
[Kutipan teks disembunyikan]

Lutchmeenaraidoo, Hema <H.Lutchmeenaraidoo@wolterskluwer.com>
Kepada: gde rurus suryawan I <igde.rurus.s@fk.unair.ac.id>

Kam, 6 Jan 2022 pukul 18.14

Dear Dr I Gde Rurus Suryawan,

The proof is not publish in an issue yet. Please find attached the final proof that we hold and will be publishing in an issue soon.

Thanks

[Kutipan teks disembunyikan]